Itoco (Dorzolamide)

Dorzolamide inhibits carbonic anhydrase enzymes in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that maintains eye pressure, thereby lowering intra‑ocular pressure and managing glaucoma or ocular hypertension.

The dosing regimen for Itoco is determined by the prescribing ophthalmologist based on the patient’s condition and response. Typically, dorzolamide eye drops are administered one or two times daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for dorzolamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Itoco (dorzolamide) belongs to the carbonic anhydrase inhibitor class, which lowers eye pressure by reducing aqueous humor production. Alternatives include beta‑blocker drops (e.g., timolol) that decrease fluid production via a different pathway, and prostaglandin analogues (e.g., latanoprost) that increase outflow. Choice depends on efficacy, tolerance, and patient‑specific factors.

Store Itoco at room temperature, preferably below 25 °C. Keep the bottle tightly closed, in its original packaging, and protect it from light and moisture. Do not freeze the solution, and discard any product that appears discolored or contaminated.

Itoco is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. Avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, corneal edema, and persistent ocular pain. If any signs of a serious reaction occur—such as rash, swelling, vision changes, or severe eye discomfort—immediate medical attention is required.

Itoco should not be used by individuals with a known hypersensitivity to dorzolamide, sulfonamides, or any component of the formulation. Patients with severe corneal disease or those using other carbonic anhydrase inhibitor eye drops without medical guidance should also avoid it.